Release Date:  August 7, 2000

RFA:  DK-01-008

National Institute of Diabetes and Digestive and Kidney Diseases
National Institute on Aging
National Cancer Institute
National Institute of Environmental Health Sciences

Letter of Intent Receipt Date:  2/27/01
Application Receipt Date:       3/27/01


This initiative is designed to explore the underlying mechanism(s) of 
action of hormones and growth factors in the regulation of prostate 
development, growth, and tumorigenesis.  The focus will be on 
fundamental studies of hormone and growth factor action including the 
mechanisms of action of nuclear hormones, the role(s) of nuclear 
accessory proteins and the signal transduction pathways important for 
nuclear hormone action in prostate.  Focus will also be on growth 
factor action in prostate, including growth factors, binding proteins, 
receptors and signal transduction pathways.  Studies are also invited 
that will examine the patterns of gene expression in the prostate in 
vivo or in prostate cells in response to hormone or growth factor 
action.  Moreover, since there are some studies that indicate that 
environmental factors also increase the risk for development of 
prostate cancer, an additional focus will be on studies that will 
explore the role of environmental factor(s) in affecting 
hormonal/growth factor action in prostate.  Finally, studies on the 
development and potential use of hormone/growth factor analogs, 
agonists, or antagonists with potential clinical utility to modify 
prostate growth and tumor development and/or progression will be 


The Public Health Service (PHS) is committed to achieving the health 
promotion and disease prevention objectives of "Healthy People 2010," a 
PHS-led national activity for setting priority areas.  {This RFA, ROLE 
priority area of hormonal carcinogenesis and prostate disease.  
Potential applicants may obtain a copy of "Healthy People 2010" at 


Applications may be submitted by domestic and foreign for-profit and 
nonprofit organizations, public and private, such as universities, 
colleges, hospitals, laboratories, units of State and local 
governments, and eligible agencies of the Federal government.  
Racial/ethnic minority individuals, women, and persons with 
disabilities are encouraged to apply as Principal Investigators.


This RFA will use the National Institutes of Health (NIH) research 
project grant (R01) and pilot and feasibility (R21) award mechanisms.  
Only new (Type 1) grant submissions will be accepted for this 
initiative.  Amended and competing continuing applications will not be 
accepted.  Applications for research project grants (R01) may be 
submitted for up to 4 years of support with first year direct cost 
budgets of no more than $225,000.  Applications for pilot and 
feasibility (R21) awards may be submitted for up to two years with 
first year direct cost budgets of no more than $100,000.  
Responsibility for the planning, direction, and execution of the 
proposed project will be solely that of the applicant.  Except as 
otherwise stated in this announcement, awards will be administered 
under NIH grants policy as stated in the NIH Grants Policy Statement.

Specific application instructions have been modified to reflect 
"MODULAR GRANT" and "JUST-IN-TIME" streamlining efforts being examined 
by the NIH.  Complete and detailed instructions and information on 
Modular Grants can be found at

Applicants from institutions that have a General Clinical Research 
Center (GCRC) funded by the NIH National Center for Research Resources 
may wish to identify the GCRC as a resource for conducting the proposed 
research.   In such a case, a letter of agreement from either the GCRC 
program director or principal investigator should be included with the 

This RFA is a one-time solicitation.  Future unsolicited competing 
continuation applications will compete with all investigator-initiated 
applications and be reviewed according to the customary peer review 
procedures.  Responsibility for the planning, direction, and execution 
of the proposed project will be solely that of the applicant.  The 
total requested project period for applications submitted in response 
to this RFA may not exceed four years (two for the R21).  The 
anticipated award date is September 28, 2001.


For FY 2001, $3,000,000 will be committed by NIDDK to fund applications 
submitted in response to this RFA.  The NIA will commit $300,000, the 
NCI will commit $1,000,000, and NIEHS will commit $300,000.  Thus, a 
total of $4,600,000 has been committed for FY 2001 to fund 
approximately 20-25 grants; however, this funding level is dependent 
upon the receipt of a sufficient number of applications of high 
scientific merit.  Although this program is provided for in the 
financial plans of the NIDDK, NIA, NCI, and NIEHS, the award of grants 
pursuant to this RFA is also contingent upon the availability of funds 
for this purpose.



Although the prostate is clearly a sex steroid (Androgen) dependent 
tissue, there is ample evidence to support roles for numerous other 
nuclear and peptide hormones, as well as growth factors and cytokines 
in the development of the tissue and the development and progression of 
tumors arising from cells within the adult tissue.  At a recent NIDDK 
International Symposium on the Biology of Prostate Growth, data were 
presented to show that factors such as the Insulin-like growth factor-I 
(IGF-I), fibroblast growth factor (FGF), members of the erbB family, 
and others, as well as their receptors and binding proteins, and other 
small bioactive peptide hormones, have been implicated in development, 
growth and differentiation of both the epithelial and the stromal 
components of prostate.  Furthermore, activation of peptide growth 
factor receptors initiates signal transduction pathways leading to 
change in cellular function and/or structure.  In some cases of 
aberrant prostate growth, the growth factor receptors are overexpressed 
or otherwise dysregulated, or are constitutively activated.  In other 
cases, components of signal transduction pathways are overexpressed or 
constitutively activated.  Additionally, agents that block receptor 
activation and/or signaling are becoming available for use in analysis 
and/or treatment of tumors.  The contribution of growth factors, such 
as IGF-I, their receptors, binding proteins and signaling pathways in 
the development and/or progression of tumors needs further 

Eicosanoids (prostaglandins) are another class of mediators that may 
also contribute to prostate growth and differentiation.  Expression of 
the inducible form of one enzyme responsible for prostaglandin 
synthesis, cyclooxygenase 2 (COX-2), has been observed in prostate 
cancer.  Pharmacologic inhibition of COX-2 activity induces apoptosis 
in prostate cancer cells.  Further, some prostaglandins act through the 
peroxisome proliferator-activated receptor (PPAR), a member of the 
nuclear hormone superfamily.  The recent availability of COX-2 
inhibitors and PPAR agonists will allow a sophisticated analysis of 
their contributions to prostate growth and tumorigenesis.

Still other cytokines and growth factors, including interleukin (IL)-6, 
members of the transforming growth factor (TGB)-beta family, and 
others, have also been implicated in the development of prostate 
cancer.  New insights into the molecular mechanism(s) of action of such 
factors through the cytokine receptor superfamily and transcription 
factors such as the Smad proteins may have relevance to prostate growth 
and or disease, as well.

While growth factors are extremely important in prostate function, 
members of the nuclear hormone superfamily play crucial roles in 
prostate development, growth, function, and tumorigenesis and/or 
progression.  Studies in developing prostate are of interest since 
signaling pathways present at that time may have important implications 
for later development of tumors.  The receptors for the nuclear 
receptor superfamily function primarily as transcription factors in the 
nucleus to either suppress or activate gene expression through effects 
on DNA transcription.  At a recent NIDDK workshop entitled “Co-
activators and Co-repressors in Gene Expression,” work was presented 
which suggested a role for the relative affinity of binding of nuclear 
accessory proteins, including co-repressors and co-activators, to form 
complexes essential to determining whether a particular gene is 
activated or not in response to hormone.  Further observations have 
pointed to mutations in nuclear accessory proteins and/or nuclear 
receptors as factors that can either cause hormone resistance or 
inappropriate gene expression.  Fusion proteins, which cause cancers, 
such as the acute myelogenous leukemia-eight to twenty-one (AML-ETO) 
fusion protein in acute myelogenous leukemia, recruit co-repressor 
complexes to block gene transcription relevant to differentiation of 
hematopoietic precursors.  These factors have now become targets for 
therapeutic intervention, as well.  In addition, mutations in one co-
activator, known as AIB1, a member of the steroid receptor coactivator 
(SRC)-1 family, have been implicated in breast cancer.  

Androgens represent the primary steroid hormone affecting gene 
expression in the prostate, though roles for estrogen and for orphan 
nuclear receptors have also been suggested.  Indeed, studies on the 
newly discovered estrogen receptor (ER)-beta have revealed high levels 
in prostate tissue, with the intriguing suggestion of a role(s) in 
prostate development, as well as in prostate hyperplasia.  Androgens 
appear to form homodimer pairs in binding to chromatin, and recruit 
nuclear accessory proteins, such as androgen receptor associated (ARA) 
70 protein.  The ARA is thus also a candidate for interaction with 
other nuclear accessory proteins, such as co-activators or co-
repressors that regulate repression or activation of target genes.  
Finally, orphan nuclear receptors--proteins structurally consistent 
with nuclear receptors but for which no known hormone exists--have been 
shown to have functions in prostate, as well (e.g., chicken ovalbumin 
upstream transcription factor, or COUP-TF, and testis associated 
receptor, or TR4).  Another recent NIH Workshop on Selective Estrogen 
Receptor Modulators (SERMS), focused on the potential utility of 
hormonal analogs, partial agonists, and antagonists as therapeutic 
agents for hormonal-dependent cancers, including those in breast and 
prostate.   Some of these Selective Receptor Modulators (SRM's) have 
already found their way into clinical use in the treatment and/or 
prevention of breast cancer (e.g., Tamoxifen), and finasteride for 
treatment of benign prostatic hypertrophy (BPH) and prostate cancer.  
The role of SRMs, which can block the androgen effects on prostate 
growth, tumor development and/or progression, remains to be determined.

Finally, the role of signal transduction cross talk between growth 
factors and nuclear/orphan receptors may mediate interactions between 
cell types in the prostate and contribute to stimulation and/or growth 
of prostate and to tumorigenesis.  This remains an important and 
largely underdeveloped consideration in understanding the development 
both of normal tissue and of disease, particularly in light of the fact 
that tumors generally become androgen-independent.  Additional studies 
have suggested a role for environmental factors as well, and thus 
understanding the overall concept of growth stimuli and growth controls 
involved in this stage represents an important area in which further 
investigation is needed.  

Thus, the specific objectives of this research solicitation include but 
are not limited to:  

o Hormonal or growth factor regulation of prostate development, 
function, growth, or tumor development

o Mechanism of action of nuclear hormones and/or peptide hormones or 
growth factors in the regulation of prostate-specific gene expression

o Novel cell culture or transgenic model systems that allow for study 
in vitro or in vivo of gene expression in prostate or prostate cells

o Role(s) of nuclear accessory proteins in regulation of hormone/growth 
factor action in prostate

o Novel factor(s) associated with nuclear hormone action in prostate 
involved in tumorigenesis

o Analogs, agonists, or antagonists of nuclear hormones/growth factors 
with potential effects on tumor development and/or progression

o Orphan nuclear receptors with role(s) in prostate structure, 
function, or disease development or progression

o Structural biology of the androgen receptor (AR) focusing on 
interactions with other receptor interacting proteins, co-activators or 
co-repressors, hormone, or hormone response elements 

o Effects of Selective Receptor Modulators (SRM's) on prostate 

o Role(s) of heat shock, or other chaperone, proteins in regulating 
androgen (and other hormone) function in prostate

o Signaling cross-talk between nuclear receptors and/or growth factor 
or cytokine, and other cell surface receptors, and effects on 
regulation of prostate gene expression and disease 

o Use of DNA arrays, bioinformatics approaches to proteomics, or in 
silico methods of analysis to evaluate gene expression during growth 
factor or hormone signaling among different cells in the prostate 
during development, stages of tumor development, or tumor progression

o Age-related changes in hormone or growth factor signaling processes 
and patterns of gene expression that may be involved in the increasing 
risk of prostate cancer with age

o A mechanism of action of nuclear hormones working through non-
receptor-mediated events leading to the initiation of cancer in 
prostate cells

o Role(s) of environmental factors that may interact with or influence 
the effects of hormones and growth factors on prostate growth, 
development, and/or tumor development


It is the policy of the NIH that members of minority groups and their 
subpopulations must be included in all NIH supported biomedical and 
behavioral research projects involving human subjects, unless a clear 
and compelling rationale and justification is provided that inclusion 
is inappropriate with respect to the health of the subjects or the 
purpose of the research.  This new policy results from the NIH 
Revitalization Act of 1993 (Section 492B of Public Law 103-43).
All investigators proposing research involving human subjects should 
read the "NIH Guidelines For Inclusion of Minorities as Subjects in 
Clinical Research," which was published in the Federal Register of 
March 28, 1994 (FR 59 14508-14513) and in the NIH Guide For Grants and 
Contracts, Vol. 23, No. 11, March 18, 1994, available on the web at:

All applications and proposals for NIH funding must be self-contained 
within specified page limitations. Unless otherwise specified in an NIH 
solicitation, internet addresses (URLs) should not be used to provide 
information necessary to the review because reviewers are under no 
obligation to view the Internet sites. Reviewers are cautioned that 
their anonymity may be compromised when they directly access an 
Internet site.


Prospective applicants are asked to submit by February 27, 2001 a 
letter of intent that includes a descriptive title of the proposed 
research; the name, address, and telephone number of the Principal 
Investigator; the identities of other key personnel and participating 
institutions; and the number and title of the RFA in response to which 
the application may be submitted.

Although a letter of intent is not required, is not binding, and does 
not enter into the review of a subsequent application, the information 
that it contains allows NIDDK staff to estimate the potential review 
workload and plan the review.

The letter of intent is to be sent to:

Chief, Review Branch 
Division of Extramural Activities, NIDDK
6707 Democracy Blvd., Room 653
Bethesda, MD 20892-5462
Bethesda, MD 20817 (for express/courier service)
Telephone:  (301) 594-8885
FAX:  (301) 480-3505


The research grant application form PHS 398 (rev. 4/98) is to be used 
in applying for these grants.  These forms are available at most 
institutional offices of sponsored research and may be obtained from 
the Division of Extramural Outreach and Information Resources, National 
Institutes of Health, 6701 Rockledge Drive, MSC 7910, Bethesda, MD 
20892-7910, telephone 301-710-0267, email:

The modular grant concept establishes specific modules in which direct 
costs may be requested as well as a maximum level for requested 
budgets. Only limited budgetary information is required under this 
approach.  The just-in-time concept allows applicants to submit certain 
information only when there is a possibility for an award. It is 
anticipated that these changes will reduce the administrative burden 
for the applicants, reviewers, and Institute staff.  The research grant 
application form PHS 398 (rev. 4/98) is to be used in applying for 
these grants, with the modifications noted below.


General instructions for use of the modular grant format include:

Modular Grant applications will request direct costs in $25,000 
modules, up to a total direct cost request of $225,000 per year for R01 
applications, or $100,000 for R21 applications. The total direct costs 
must be requested in accordance with the program guidelines and the 
modifications made to the standard PHS 398 application instructions 
described below, and as noted in the NIH Guide announcement for modular 
grants (

FACE PAGE: Items 7a and 7b should be completed, indicating Direct Costs 
(in $25,000 increments up to a maximum of $225,000 or $100,000) and 
Total Costs [Modular Total Direct plus Facilities and Administrative 
(F&A) costs] for the initial budget period.  Items 8a and 8b should be 
completed indicating the Direct and Total Costs for the entire proposed 
period of support.

Page 4 of the PHS 398. It is not required and will not be accepted with 
the application.

the categorical budget table on Form Page 5 of the PHS 398.  It is not 
required and will not be accepted with the application.

o NARRATIVE BUDGET JUSTIFICATION:  Prepare a Modular Grant Budget 
Narrative page. (See for sample 
pages.)  At the top of the page, enter the total direct costs requested 
for each year.  This is not a Form page.

o Under Personnel, list ALL project personnel, including their names, 
percent of effort, and roles on the project. No individual salary 
information should be provided. However, the applicant should use the 
NIH appropriation language salary cap and the NIH policy for graduate 
student compensation in developing the budget request.

For Consortium/Contractual costs, provide an estimate of total costs 
(direct plus facilities and administrative) for each year, each rounded 
to the nearest $1,000.  List the individuals/organizations with whom 
consortium or contractual arrangements have been made, the percent 
effort of key personnel, and the role on the project.  Indicate whether 
the collaborating institution is foreign or domestic.  The total cost 
for a consortium/contractual arrangement is included in the overall 
requested modular direct cost amount.  Include the Letter of Intent to 
establish a consortium.  Indirect costs for subcontracts are included 
in the total costs for the application and should also be in modular 
form.  Provide an additional narrative budget justification for any 
variation in the number of modules requested.

o BIOGRAPHICAL SKETCH:  The Biographical Sketch provides information 
used by reviewers in the assessment of each individual's qualifications 
for a specific role in the proposed project, as well as to evaluate the 
overall qualifications of the research team. A biographical sketch is 
required for all key personnel, following the instructions below.  No 
more than three pages may be used for each person. A sample 
biographical sketch may be viewed at:

- Complete the educational block at the top of the form page;
- List position(s) and any honors;
- Provide information, including overall goals and responsibilities, on 
research projects ongoing or     completed during the last three years.
- List selected peer-reviewed publications, with full citations.

o CHECKLIST:  This page should be completed and submitted with the 
application. If the F&A rate agreement has been established, indicate 
the type of agreement and the date. All appropriate exclusions must be 
applied in the calculation of the F&A costs for the initial budget 
period and all future budget years.

o The applicant should provide the name and phone number of the 
individual to contact concerning fiscal and administrative issues if 
additional information is necessary following the initial review.  

Applicants should carefully read the specific text of this RFA for 
budgetary constraints applying to this particular initiative.

The RFA label available in the PHS 398 (rev. 4/98) application form 
must be affixed to the bottom of the face page of the application.  
Failure to use this label could result in delayed processing of the 
application such that it may not reach the review committee in time for 
review.  In addition, the RFA title and number must be typed on line 2 
of the face page of the application form and the YES box must be 

The sample RFA available at: has been modified 
to allow for this change.  Please note this is in pdf format.

Submit a signed, typewritten original of the application, including the 
Checklist, and three signed photocopies, in one package to:

Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040 - MSC 7710
Bethesda, MD 20892-7710
Bethesda, MD 20817 (for express/courier service)

At time of submission, two additional copies of the application must be 
sent to:

Chief, Review Branch
6707 Democracy Blvd., Room 653
Division of Extramural Activities, NIDDK
Bethesda, MD 20892-5452
Bethesda, MD 20817 (for express/courier service)

Applications must be received by March 27, 2001.  If an application is 
received after that date, it will be returned to the applicant without 
review.  Similarly, supplemental documents containing significant 
revision or additions will not be accepted after that date, unless 
applicants are notified by the Scientific Review Administrator.  The 
Center for Scientific Review (CSR) will not accept any application in 
response to this RFA that is essentially the same as one currently 
pending initial review, unless the applicant withdraws the pending 
application.  The CSR will not accept any application that is 
essentially the same as one already reviewed.  


Applications that are complete and responsive to the RFA will be 
evaluated for scientific and technical merit by an appropriate peer 
review group  (special emphasis panel) convened by the NIDDK in 
accordance with the review criteria stated below.  As part of the 
initial merit review, all applications will receive a written critique 
and undergo a process in which only those applications deemed to have 
the highest scientific merit, generally the top half of the 
applications under review, will be discussed, assigned a priority 
score, and receive a second level review by the National Diabetes and 
Digestive and Kidney Diseases Advisory Council.

Review Criteria

The goals of NIH-supported research are to advance our understanding of 
biological systems, improve the control of disease, and enhance health.  
In the written comments, reviewer will be asked to discuss the 
following aspects of the application in order to judge the likelihood 
that the proposed research will have a substantial impact on the 
pursuit of these goals.  Each of these criteria will be addressed and 
considered in assigning the overall score, weighting them as 
appropriate for each application.  Note that the application does not 
need to be strong in all categories to be judged likely to have major 
scientific impact and thus deserve a high priority score.  For example, 
an investigator may propose to carry out important work that by its 
nature is not innovative but is essential to move a field forward.

o Significance:  Does this study address an important problem?  If the 
aims of the application are achieved, how will scientific knowledge be 
advanced?  What will be the effect of these studies on the concepts or 
methods that drive this field?

o Approach:  Are the conceptual framework, design, methods, and 
analyses adequately developed, well-integrated, and appropriate to the 
aims of the project?  Does the applicant acknowledge potential problem 
areas and consider alternative tactics?

o Innovation:  Does the project employ novel concepts, approaches or 
method? Are the aims original and innovative?  Does the project 
challenge existing paradigms or develop new methodologies or 

o Investigator:  Is the investigator appropriately trained and well 
suited to carry out this work?  Is the work proposed appropriate to the 
experience level of the principal investigator and other researchers 
(if any)?

o Environment:  Does the scientific environment in which the work will 
be done contribute to the probability of success?  Do the proposed 
experiments take advantage of unique features of the scientific 
environment or employ useful collaborative arrangements?  Is there 
evidence of institutional support?

In addition to the above criteria, in accordance with NIH policy, all 
applications will also be reviewed with respect to the following:

o Adequacy of plans to include minorities and their subgroups, as 
appropriate for the scientific goals of the research.  Plans for the 
recruitment and retention of subjects will also be evaluated. 

o The reasonableness of the proposed budget and duration to the 
proposed research.

o The adequacy of the proposed protection of humans, animals, or the 
environment, to the extent that they may be adversely affected by the 
project proposed in the application.

For applicants from foreign institutions:

o Availability of special opportunities for furthering research 
programs through the use of unusual talent resources, populations, or 
environmental conditions in other countries which are not readily 
available in the United States or which provide augmentation of 
existing U.S. resources.


The anticipated date of award is September 28, 2001.

Award criteria that will be used to make award decisions include:

o Scientific merit as determined by peer review;

o Availability of funds;

o Programmatic priorities.


Inquiries concerning this RFA are encouraged.  The opportunity to 
clarify any issues or questions from potential applicants is welcomed.

Direct inquiries regarding programmatic issues relevant to NIDDK to:

Ronald Margolis, Ph.D.
Senior Advisor, Molecular Endocrinology 
Division of Diabetes, Endocrinology, and Metabolic Diseases
6707 Democracy Blvd.
Room 6107
Bethesda, MD 20892-5460
Telephone:  (301) 594-8819
FAX: 301-435-6047

Monica Liebert, Ph.D.
Director, Basic Science Programs in Urology
Division of Kidney, Urology and Hematology
6707 Democracy Blvd.
Room 623
Bethesda, MD 20892-5460
Telephone:  (301) 594-1409
FAX: 301-480-3510

Direct inquiries regarding fiscal and administrative matters to:

Cheryl Chick
Grants Management Specialist
Division of Extramural Activities 
Bethesda, MD 20892-5460
Telephone:  (301) 594-8825
FAX:  (301) 594-3504

Trude Hilliard
Grants Management Specialist
Division of Extramural Activities 
Bethesda, MD 20892-5460
Telephone:  (301) 594-8859
FAX:  (301) 594-3504

Direct inquiries regarding programmatic issues relevant to NIA to:

Frank Bellino, PhD
Deputy Associate Director
Endocrinology Program Administrator
Biology of Aging Program
National Institute on Aging
Gateway Bldg., Suite 2C231
Bethesda, MD  20892-9205
Telephone: (301) 496-6402
FAX: (301) 402-0010

Direct inquiries regarding fiscal and administrative matters to: 

Crystal Ferguson
Grants Management Office
National Institute on Aging
Gateway Building, Suite 2N212
Bethesda, MD  20892-9205
Telephone:  (301) 496-1472
FAX: (301) 402-3672

Direct inquiries regarding programmatic issues relevant to NCI to:

Suresh Mohla, Ph.D.
Chief, Tumor Biology and Metastasis Branch
Division of Cancer Biology
National Cancer Institute
6130 Executive Boulevard
EPN Suite 5000
Rockville MD 20892-7364
Telephone : (301) 435-1878
FAX : (301) 480-0864
Direct inquiries regarding fiscal and administrative matters to:

Ms. Crystal Wolfrey
Lead Grants Management Specialist
Grants Administration Branch
National Cancer Institute
Executive Plaza South, Room 243
6120 Executive Blvd., MSC 7150
Rockville, Maryland 20892-7150
Telephone: (301) 496-8634
FAX:  (301) 496-8601

Direct inquiries regarding programmatic issues relevant to NIEHS to:

Michael E. McClure, Ph.D.
Chief, Organs and Systems Toxicology Branch                        
Division of Extramural Research and Training                           
National Institute of Environmental Health Sciences, NIH     
111 T.W. Alexander Drive
Courier: 79 T.W. Alexander Dr
P.O. Box 12233, Mail Drop EC-23
Bldg. 4401, Rm. 3417
Research Triangle Park, North Carolina 27709
RTP. NC 27709
Telephone: (919) 541-5327  
FAX: (919) 541-5064

Direct inquiries regarding fiscal and administrative matters to:

Dorothy Duke
Division of Extramural Research and Training
National Institute of Environmental Health Science
Box 12233, MD EC-22
Research Triangle Park, NC 27709
Telephone:  (919) 541-1373
FAX:  (919) 541-2860

This program is described in the Catalog of Federal Domestic Assistance 
No.  93.847 for DEM and 93-848 for KUH, No. 93.866 for NIA, No. 93.394 
for NCI, and No. 93.113 and 93.866.  Awards are made under 
authorization of the Public Health Service Act, Title IV, Part A 
(Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 
285) and administered under NIH grants policies and Federal Regulations 
42 CFR 52 and 45 CFR Part 74.  This program is not subject to the 
intergovernmental review requirements of Executive Order 12372 or 
Health Systems Agency review.

The NIH strongly encourages all grant and contract recipients to 
provide a smoke-free workplace and promote the non-use of all tobacco 
products.  In addition, Public Law 103-227, the Pro-Children Act of 
1994, prohibits smoking in certain facilities (or in some cases, any 
portion of a facility) in which regular or routine education, library, 
day care, health care or early childhood development services are 
provided to children.  This is consistent with the NIH mission to 
protect and advance the physical and mental health of the American 

Return to Volume Index

Return to NIH Guide Main Index

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.